The prevalence of anti-cyclic citrullinated peptide (anti-CCP) antibodies in patients with thyroid autoimmunity
Tiroid otoimmünitesi olan hastalarda anti-siklik sitrülinlenmiş peptit (anti-CCP) antikor yaygınlığı
1 Ankara Numune Eğitim ve Araştırma Hastanesi, Romatoloji Kliniği, Ankara, Türkiye
2 Ankara Eğitim ve Araştırma Hastanesi, Endokrinoloji ve Metabolizma Hastalıkları Kliniği, Ankara, Türkiye
3 Hitit Üniversitesi Tıp Fakültesi, Çorum, Türkiye
* Corresponding Author
Ortadogu Tıp Derg, Volume 8, Issue 4, pp. 182-185
Anti-cyclic citrullinated peptide (anti-CCP) antibodies are one of the diagnostic markers of rheumatoid arthri- tis (RA), but can also be found in other diseases such as systemic lupus erythematosus, primary Sjogren’s syndrome. So far, there has been no data available which identified prevalence of anti-CCP in patients with thyroid autoimmun- ity (TA). We aimed to identify anti-CCP prevalence in adult patients with TA.
Material and Methods: We reviewed retrospectively medical records of 1282 patients including TPO-Ab, TRAb, rheumatoid factor (RF), anti-CCP antibodies in the computer database between the dates of January 2010 and Oc- tober 2014. TA diagnosis was made if thyroid autoantibodies were higher than the upper limit of normal. Anti-CCP and RF positivity were considered if the values exceeded the upper limit of normal. Patients with or without TA were compared in terms of the prevalence of anti-CCP antibodies.
Results:In group with TA, TPO-Ab, TRAb, CCP, and RF were detected in 332 (99%), 7 (2%), 44 (13%), and 78 (23%) patients respectively. In group without TA, CCP was detected in 70 patients (7.4%), and RF was detected in 378 (20%) patients. The positive rates of anti-CCP were significantly higher in patients with TA than the patients without TA (13% vs.7.4%, p<0.001). However, there was no difference in RF positivity between the groups.
Conclusion: Our study indicates an increased prevalence of anti-CCP antibodies in patients with TA. It is suggested that anti-CCP antibodies can also be shown in patients with TAin addition to RA.
Omma, A., Sandıkçı, S. C., Omma, T., & Karaaslan, Y. (2016). The prevalence of anti-cyclic citrullinated peptide (anti-CCP) antibodies in patients with thyroid autoimmunity.
Ortadoğu Tıp Dergisi, 8(4), 182-185.
https://doi.org/10.21601/ortadogutipdergisi.292160
Omma, A., Sandıkçı, S. C., Omma, T., and Karaaslan, Y. (2016). The prevalence of anti-cyclic citrullinated peptide (anti-CCP) antibodies in patients with thyroid autoimmunity.
Ortadoğu Tıp Dergisi, 8(4), pp. 182-185.
https://doi.org/10.21601/ortadogutipdergisi.292160
Omma, Ahmet, Sevinç Can Sandıkçı, Tülay Omma, and Yaşar Karaaslan. "The prevalence of anti-cyclic citrullinated peptide (anti-CCP) antibodies in patients with thyroid autoimmunity".
Ortadoğu Tıp Dergisi 2016 8 no. 4 (2016): 182-185.
https://doi.org/10.21601/ortadogutipdergisi.292160